1 / 10

Featured Article :

Featured Article :. New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1).

krista
Download Presentation

Featured Article :

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Featured Article: New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1) Matthew C. Riddle, Geremia B. Bolli, Monika Ziemen, Isabel Muehlen-Bartmer, Florence Bizet, and Philip D. Home, on behalf of the EDITION 1 Study Investigators Diabetes Care Volume 37: 2755-2762 October, 2014

  2. STUDY OBJECTIVE • To compare the efficacy and safety of new insulin glargine 300 units/mL (Gla-300) with glargine 100 units/mL (Gla-100) in people with type 2 diabetes on basal insulin plus mealtime insulin Riddle M. C. et al. Diabetes Care 2014;37:2755-2762

  3. STUDY DESIGN AND METHODS • EDITION 1 was a 6-month, multinational, open-label, parallel-group study • Adults with HbA1c of 7.0–10.0% were randomized to Gla-300 or Gla-100 once daily, with dose titration seeking fasting plasma glucose of 4.4–5.6 mmol/L • Primary end point was HbA1c change from baseline • Main secondary end point was percentage of participants with one or more confirmed or severe nocturnal hypoglycemia from week 9 to month 6 Riddle M. C. et al. Diabetes Care 2014;37:2755-2762

  4. RESULTS • Participants had mean age 60 years, diabetes duration 16 years, BMI 36.6 • kg/m2, and HbA1c 8.15% • HbA1c reduction was equivalent between regimens • Fewer participants reported one or more confirmed or severe nocturnal hypoglycemic events between week 9 and month 6 with Gla-300 • Nocturnal hypoglycemia incidence and event rates were also lower with Gla-300 in the first 8 weeks of treatment • No between-treatment differences in tolerability or safety were identified Riddle M. C. et al. Diabetes Care 2014;37:2755-2762

  5. Riddle M. C. et al. Diabetes Care 2014;37:2755-2762

  6. Riddle M. C. et al. Diabetes Care 2014;37:2755-2762

  7. Riddle M. C. et al. Diabetes Care 2014;37:2755-2762

  8. CONCLUSIONS • Gla-300 controls HbA1c as well as Gla-100 for people with type 2 diabetes treated with basal and mealtime insulin, but with consistently less risk of nocturnal hypoglycemia Riddle M. C. et al. Diabetes Care 2014;37:2755-2762

  9. Riddle M. C. et al. Diabetes Care 2014;37:2755-2762

  10. Riddle M. C. et al. Diabetes Care 2014;37:2755-2762

More Related